Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone reflects strong agreement with the article's assertion about increasing R&D costs, with comments referencing specific figures like $2.87 billion, and discussing the broader implications for industry and policy. Words like 'soaring', 'monstrous sums', and 'must-read' emphasize the perceived importance and potential influence of the research findings.
Most discussions acknowledge the high costs of R&D and validate the article's findings, reflecting consensus on the rising industry expenses.
Posts show a strong curiosity about drug development costs, regulatory impacts, and industry implications, indicating high interest.
Several commenters reference studies, critique methodologies, or discuss regulatory and industry consequences, demonstrating a moderate level of engagement.
The discussions highlight the significance of the cost estimates for policy, industry strategy, and healthcare economics, suggesting a notable impact.
Closest I can see is DiMasi 2016 (https://t.co/aCVbLFBQNc) but they do not have failed pre-clinical compound data, just cost per phase/approved compound
@stephensenn https://t.co/VQnPKGmnDF and https://t.co/WoueA8hmo3
Below is what happens when the White House takes advice from the Arnold Foundation/ICER & the health insurance industry/PBMs on drug development. Check with Tufts for a few minutes on the level of investment it takes just for 1 new drug ('13-'14 data): https://t.co/bE3leuRigf https://t.co/5Y05dwUcjX
R&D is increasing exponentially. The primary drivers behind soaring R&D are the increasing regulatory demands by the @US_FDA ("Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs." Journal of Health Economics, May;47: 20–33) https://t.co/KbIeoSexui
@sarah_cone @heyjudka @menten_ai Economist Joseph DiMasi created @TuftsCSDD . With collaborators Grabowski @DukeU Hansen @rochester_u , he has studied this over time. https://t.co/sWOJfnCfGH
@stopexpo2025 @hiroyoshimura 創薬コストは先行研究の推定よりも大幅に小さいものであった（https://t.co/9BquSaGwnM）。一般に高額な薬価が正当化されるのは、新薬の開発は多額のコストを要すると想定されているからであるが、本研究の分析はこうした信念に疑問を投げかける。
This video explains the key goals in each phase of clinical trials and discusses the probability of success, with insights into the high costs involved in R&D as highlighted in recent industry studies.
Full Video httpsyoutubeZEinltRLJnU Shorts. This video explains the clinical trial process and reviews the high R&D costs involved in developing new drugs, with average expenses reaching over 2.8 billion dollars in 2013…
@marukun_1028 @KEa92vx5BiIh6Ox 創薬コストは先行研究の推定よりも大幅に小さいものであった（https://t.co/t7m0B6Oabt）。一般に高額な薬価が正当化されるのは、新薬の開発は多額のコストを要すると想定されているからであるが、本研究の分析はこうした信念に疑問を投げかける。
@stopexpo2025 @hiroyoshimura 創薬コストは先行研究の推定よりも大幅に小さいものであった（https://t.co/9BquSaGwnM）。一般に高額な薬価が正当化されるのは、新薬の開発は多額のコストを要すると想定されているからであるが、本研究の分析はこうした信念に疑問を投げかける。
Supporting Evidence: * DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ.2016;47:20-33. doi:10.1016/j.jhealeco.2016.01.012. * Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug
RT @PearlF: Below is what happens when the White House takes advice from the Arnold Foundation/ICER & the health insurance industry/PBMs on…
Below is what happens when the White House takes advice from the Arnold Foundation/ICER & the health insurance industry/PBMs on drug development. Check with Tufts for a few minutes on the level of investment it takes just for 1 new drug ('13-'14 data): https://t.co/bE3leuRigf https://t.co/5Y05dwUcjX
For those of y'all interested in working in pharma/biotech, this is practically a must-read https://t.co/ekPB3u7EFu
@stephensenn https://t.co/VQnPKGmnDF and https://t.co/WoueA8hmo3
@sarah_cone @heyjudka @menten_ai Economist Joseph DiMasi created @TuftsCSDD . With collaborators Grabowski @DukeU Hansen @rochester_u , he has studied this over time. https://t.co/sWOJfnCfGH
Innovation in the pharmaceutical industry: New estimates of R&D costs https://t.co/RalowakUxa
The paper published in the Journal of Health Economics reveals soaring prices of the R&D. A production cost for one drug can go as high as $2870 million, and total capitalized costs increase at an annual rate of 8.5% above general price inflation. https://t.co/2Phm7FMNv4
Closest I can see is DiMasi 2016 (https://t.co/aCVbLFBQNc) but they do not have failed pre-clinical compound data, just cost per phase/approved compound
@TomiHaataja @joonahermanni https://t.co/Gc8oQx68T1 https://t.co/6bQi9eIbyN
Innovation in the pharmaceutical industry: New estimates of R&D costs https://t.co/xpGa0KGjxA
@jimcramer Let’s talk about research project failure b/c from work like https://t.co/phPKFajpV4 only 12% projects succeed. We see 100s of projects but many (vaccines+antibodies) are “correlated assets” in Street parlance. The risk 0 work is real How will industry diversify this portfolio?
@Senficon @clemensv @digihumanrights @taval Das können sich kassen nie im Leben leisten. Das sind monströse Summen. https://t.co/OtOWTfgE8c
R&D is increasing exponentially. The primary drivers behind soaring R&D are the increasing regulatory demands by the @US_FDA ("Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs." Journal of Health Economics, May;47: 20–33) https://t.co/KbIeoSexui
AW
HO
PF
MD
CL
C
NH
K
TC
IS
MG
OH
AM
BC
KJ